Source: Flickr user Simon & His Camera .Love is in the air, and that makes it the perfect time to confess my affection for three large-cap biotech stocks that market a slate of highly profitable, market-share leading therapies. Read on to learn more about why I have fallen for each of them.No. 1: Celgene CorporationWhile other companies hem and haw […]
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to jump into the biotechs researching new drugs?Industry Focus takes a look at Regulus Therapeutics and Achillion Pharmaceuticals […]
Not many investment pros managed to dump their oil stocks before the price of crude started plummeting last year, but prescient investors who did obviously escaped heavy losses. The big question: Where did they invest the proceeds for greater future gains?One top-ranked money manager, Graham Tanaka, president and senior analyst and portfolio manager at TANAKA Growth Fund (TGFRX), was one […]
VIDEO UPDATE: Market analysis looking at long term charts, movers on the day, and analysis of 50 stocks with setups and buy points.It was another good day for the indexes and oil as they moved in concert. The S&P 500 gained 1.44% and the NASDAQ 1.09%. Factory orders for December posted a greater-than-expected decline of 3.4%. Analysts expected a decline […]
VIDEO UPDATE: 30m session looking at the long term market charts, top 5 movers on the day, some education, and a kickoff with a personal story of how a stop loss order I had on AMZN bit me for $2,000+, ouch.Indexes finished off a volatile session with strong gains in the closing hour as the S&P 500 closed up 1.30% […]
It’s been shown that dividend-paying stocks outperform their non-dividend paying counterparts, but focusing on dividends may not be the best strategy when it comes to big biotech stocks. Read on to learn why three Motley Fool contributors don’t think it makes sense for these big biotech companies to pay investors a dividend.Cheryl Swanson : Take a little trip through history […]
Source: StockMonkeys.com via Flickr.It’s been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead’s share price tied to the approval of AbbVie ‘s Viekira Pak and its subsequent multi-year agreement with Express Scripts , Gilead shares are up 25% for the year, essentially doubling the return of the S&P 500 […]
Biotechnology’s mind-numbing share price volatility means that only the most risk-tolerant investors should consider owning them — but for investors with a penchant for risk and a stomach tough enough to handle the inevitable pops and drops, there may be opportunities to discover emerging biotech companies with promising pipelines that could send their shares significantly higher in 2015. Ophthotech Corporation […]
View gallery.It’s been a rough couple of days for biotech stocks.To start, Gilead Sciences, Inc. (NASDAQ: GILD) has dropped from a high of almost $110 per share on Friday to a low of $86 on Tuesday.Many other big-name biotechs, such as Amgen, Inc. (NASDAQ: AMGN), Biogen Idec Inc (NASDAQ: BIIB) and Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have fallen with […]
By Ben LevisohnLeerink’s Howard Liang and team think 2015 will be another good year for biotech stocks like Gilead Sciences (GILD), Celgene (CELG), Amgen (AMGN ) and Alexion Pharmaceuticals (ALXN). They explain why:
Boston Globe via Getty Images
Biotech fundamentals appear strong, and could attract and broaden investor interest in the sector. Ongoing and upcoming product launches could be among the fastest […]
